MHCC97H Xenograft Model Service for Liver Cancer

The MHCC97H cell line provides a high-metastatic potential in vivo platform for investigating the aggressive invasive mechanisms and therapeutic responses of hepatocellular carcinoma (HCC). As a specialized pre-clinical contract research organization, Alfa Cytology delivers an integrated, high-precision MHCC97H Xenograft Model Service, meticulously optimized to provide reproducible, audit-ready data packages that accelerate your liver cancer drug discovery and development pipeline.

Overview of MHCC97H Xenograft Model for Liver Cancer

The MHCC97H xenograft model is an advanced in vivo translational system widely utilized in oncology research for studying highly invasive and metastatic hepatocellular carcinoma. By transplanting human MHCC97H cells into immunodeficient rodent hosts, this model effectively reproduces the aggressive tumor growth, local vascular invasion, and spontaneous pulmonary metastasis patterns characteristic of advanced human liver cancer.

Biologically, the MHCC97H model is distinguished by its high metastatic potential, making it an ideal system for evaluating therapies aimed at inhibiting tumor cell migration, invasion, and metastatic dissemination. The model maintains critical human liver cancer molecular features, including the expression of EMT (epithelial-mesenchymal transition) markers and robust responsiveness to both molecularly targeted agents and standard chemotherapeutic regimens. Consequently, the MHCC97H model is extensively deployed in pre-clinical screening programs to assess the anti-metastatic and anti-tumor potency of novel compounds in a physiologically relevant in vivo setting.

Fig 1. RGS14 expression in HCC cells (A) and validation of overexpression/knockdown (B-D) by Western blot. (Liang X., et al., 2025)

Cell Line Information: MHCC97H

The MHCC97H cell line is derived from human hepatocellular carcinoma and is specifically characterized by its high metastatic capacity. These cells grow as adherent cultures under standard in vitro laboratory parameters, maintaining a stable, aggressive phenotype suitable for sophisticated metastasis-focused research.

Our Services

Workflow of MHCC97H Xenograft Model Construction

• Cell Culture & Quality Control: Human MHCC97H cells are expanded in vitro using certified nutrient media under optimized physiological parameters. STR authentication and mycoplasma screening are performed prior to inoculation to ensure absolute genetic identity and purity.
• Host Selection & Preparation: Immunodeficient mice (e.g., BALB/c nude or NCG) are sourced from validated vendors and acclimatized to facility conditions to stabilize baseline biological metrics.
• Precision Inoculation: A calibrated suspension of high-viability MHCC97H cells, often supplemented with an extracellular matrix (e.g., Matrigel) to enhance take rates, is inoculated in vivo. For metastatic evaluation, orthotopic (intrahepatic) or subcutaneous injection methods are employed to facilitate tumor development and subsequent distant spread.
• Longitudinal Monitoring: Tumor dimensions are systematically measured using digital calipers. Metastatic progression is monitored via clinical observation and, if required, endpoint histological analysis to quantify lung metastasis burden.
• Randomization & Treatment: Once solid tumors reach a predefined, statistically significant volume, the animals are randomized into experimental cohorts to ensure baseline parity before the initiation of customized therapeutic dosing regimens.

Fig 2. MHCC97H Xenograft Model Construction Workflow

Case Study - MHCC97H Xenograft Model Development

A pre-clinical validation study was conducted using the MHCC97H xenograft model to evaluate the therapeutic efficacy of a novel anti-metastatic agent designed for hepatocellular carcinoma. Following precision inoculation of MHCC97H cells into immunodeficient mice, the animals developed aggressive solid tumors with secondary pulmonary metastatic spread. Animals assigned to the active treatment group demonstrated a statistically significant reduction in both primary tumor volume and the frequency of distant metastatic nodules compared to the vehicle control, confirming the model's high sensitivity and predictive reliability for screening targeted liver cancer therapies.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Profound experience in managing diverse solid tumor lineages, providing highly reproducible in vivo translational platforms for liver cancer research.
• Rigorous Quality Control: Meticulous cell validation and standardized operating procedures that minimize experimental variability across all project stages.
• Tailored Experimental Design: Highly flexible protocols that adapt to specific animal strain requirements, custom dosing schedules, and unique compound properties.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready report providing comprehensive tumor growth metrics and statistical validations.

Contact us

Accelerating your liver cancer drug pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing using our MHCC97H platform, please reach out to us today to discuss your project requirements with our expert scientific team.

For research use only. Not intended for any clinical use.